HIV/AIDS in South Africa

Black AIDS Institute Welcomes Harold Phillips as Director of the White House Office of National AIDS Policy

Retrieved on: 
Tuesday, June 15, 2021
Black AIDS Institute, HIV/AIDS in South Africa, National Minority AIDS Council

LOS ANGELES, June 15, 2021 /PRNewswire/ --Black AIDS Institute (BAI), the nation's only Black HIV organization focused on ending HIV in Black communities, welcomes Harold J. Phillips, as the new Director of the White House Office of National AIDS Policy, which has been recently reinstated by President Biden.

Key Points: 
  • LOS ANGELES, June 15, 2021 /PRNewswire/ --Black AIDS Institute (BAI), the nation's only Black HIV organization focused on ending HIV in Black communities, welcomes Harold J. Phillips, as the new Director of the White House Office of National AIDS Policy, which has been recently reinstated by President Biden.
  • His appointment, announced on 40th anniversary of AIDS, is in complete alignment with the Black AIDS Institute's " We The People: A Black Strategy To End HIV ," that advocates for elevating Black leaders in the HIV community and addressing HIV as a racial justice issue.
  • Founded in 1999, Black AIDS Institute (BAI) is the only uniquely and unapologetically Black think and do tank in America.
  • Our mission is to stop the AIDS epidemic in Black communities by engaging and mobilizing Black institutions and individuals to confront HIV.

APLA Health Commemorates the 40th Anniversary of the AIDS Epidemic

Retrieved on: 
Thursday, June 3, 2021
APLA Health, HIV/AIDS, APLA, Medical specialties, Virology, HIV/AIDS activism, HIV/AIDS in the United States, HIV/AIDS in South Africa, Michael S. Gottlieb, AIDS Walk

AIDS Project Los Angeles was formed a year later, with a mission to provide support for people with AIDS.

Key Points: 
  • AIDS Project Los Angeles was formed a year later, with a mission to provide support for people with AIDS.
  • Forty years later, more than 32.7 million people have died from AIDS-related complications worldwide, AIDS Project Los Angeles is now APLA Health, and Dr. Gottlieb is one of our distinguished resident physicians.
  • Forty years later, we are still living with HIV and AIDS, said Craig E. Thompson, CEO of APLA Health.
  • APLA Health has been able to continue to change the way we treat those living with HIV.

Teen Art Phenomenon launches Fine Art Challenge to help African Children affected by COVID19

Retrieved on: 
Wednesday, February 24, 2021
46664, HIV/AIDS in South Africa, Nelson Mandela

TORONTO, Feb. 24, 2021 /PRNewswire/ - Teen art wunderkind, Evan Sharma, is launching the CovART Challenge, an online fine art auction with a goal of funding 250,000 meals for children in Africa whose food supply and education have been devastated by COVID-19.

Key Points: 
  • TORONTO, Feb. 24, 2021 /PRNewswire/ - Teen art wunderkind, Evan Sharma, is launching the CovART Challenge, an online fine art auction with a goal of funding 250,000 meals for children in Africa whose food supply and education have been devastated by COVID-19.
  • Sharma, who grew up hearing stories of the richness of Africa from two of his grandparents who were born there, decided to help.
  • The 2-week challenge will end with the release of Sharma's 46664- a portrait of iconic South African leader, Nelson Mandela.
  • To learn more about the CovART Challenge, please visit: www.covartchallenge.com
    The CovART Challenge is a fine art auction started by teen artist Evan Sharma to raise funds for children in Africa affected by COVID19.

First-Ever All-Digital AIDS Walk Los Angeles Continues to Fight the HIV/AIDS Epidemic with Innovative Event

Retrieved on: 
Thursday, September 17, 2020
HIV/AIDS in the United States, HIV/AIDS, HIV/AIDS activism, AIDS Walk, APLA Health, AIDS service organization, HIV/AIDS in South Africa, AIDS Walk Boston, HIV/AIDS denialism

Los Angeles, CA, Sept. 17, 2020 (GLOBE NEWSWIRE) -- The first-ever all-digital AIDS Walk Los Angeles ended this past weekend, with hundreds of individual and team fundraisers, community partners, and sponsors collectively raising $974,058 on behalf of AIDS service organizations in Los Angeles County.

Key Points: 
  • Los Angeles, CA, Sept. 17, 2020 (GLOBE NEWSWIRE) -- The first-ever all-digital AIDS Walk Los Angeles ended this past weekend, with hundreds of individual and team fundraisers, community partners, and sponsors collectively raising $974,058 on behalf of AIDS service organizations in Los Angeles County.
  • AIDS Walk Los Angeles is our opportunity to let everyone know that HIV and AIDS are still prevalent and that people living with HIV or at risk of HIV need our help.
  • Every year, the money raised at AIDS Walk Los Angeles goes to support vital Care, Support and Education programs at APLA Health, Thompson continued.
  • About AIDS Walk Los Angeles: Since 1985, AIDS Walk Los Angeles has drawn hundreds of thousands of supporters to walk, and millions more to donate, raising more than $90 million to combat HIV and AIDS.

AHF: Stop the Global AIDS Drug Stock Outs!

Retrieved on: 
Monday, July 6, 2020
AIDS, Public policy, Government, Health, Infectious diseases, Other Policy Issues, Other Government, Pharmaceutical, AIDS Healthcare Foundation, Health, Contents, Medical specialties, HIV/AIDS in South Africa, HIV/AIDS

AIDS Healthcare Foundation ( AHF ) today called on governments, global health organizations and pharmaceutical companies the world over to work together to swiftly overcome barriers and eliminate stock outs of lifesaving AIDS medicines which the World Health Organization ( WHO ) has blamed on the global coronavirus pandemic.

Key Points: 
  • AIDS Healthcare Foundation ( AHF ) today called on governments, global health organizations and pharmaceutical companies the world over to work together to swiftly overcome barriers and eliminate stock outs of lifesaving AIDS medicines which the World Health Organization ( WHO ) has blamed on the global coronavirus pandemic.
  • WHO reports AIDS drug stock outs in two dozen countries with an additional 73 countries warning they are or may be at risk of stocks running out.
  • Nearly 24-million people living with HIV or AIDS today are on treatmenta remarkable accomplishment.
  • AHF says the current global AIDS drug shortages blamed on COVID-19 also confirm the need for vastly improved global public health planning, coordination and strategic stockpiling.

Update: GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial

Retrieved on: 
Thursday, February 6, 2020
Medical specialties, Health, Medicine, HIV/AIDS in the United States, HIV Vaccine Trials Network, HIV/AIDS in South Africa, GeoVax, Vaccines, HIV/AIDS research, RV 144, HIV vaccine, Vaccine

HVTN 702 was based on the only vaccine regimen ever to show protection from HIVthe regimen tested in the RV144 clinical trial in Thailand led by the U.S. Military HIV Research Program and the Thai Ministry of Health.

Key Points: 
  • HVTN 702 was based on the only vaccine regimen ever to show protection from HIVthe regimen tested in the RV144 clinical trial in Thailand led by the U.S. Military HIV Research Program and the Thai Ministry of Health.
  • For HVTN 702, the vaccine regimen was adapted to the HIV subtype Clade C most common in southern Africa, where the pandemic is most pervasive.
  • David Dodd, GeoVax President & CEO, commented, The failure of the HVTN 702 vaccine regimen to prevent HIV infection is a disappointment to everyone in the field, especially to those most closely associated with the conduct of the trial.
  • GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel vaccine platform (GV-MVA-VLPTM).

GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial

Retrieved on: 
Thursday, February 6, 2020
Medical specialties, Health, Medicine, HIV/AIDS in the United States, HIV Vaccine Trials Network, HIV/AIDS in South Africa, GeoVax, Vaccines, HIV/AIDS research, RV 144, HIV vaccine, Vaccine

HVTN 702 was based on the only vaccine regimen ever to show protection from HIVthe regimen tested in the RV144 clinical trial in Thailand led by the U.S. Military HIV Research Program and the Thai Ministry of Health.

Key Points: 
  • HVTN 702 was based on the only vaccine regimen ever to show protection from HIVthe regimen tested in the RV144 clinical trial in Thailand led by the U.S. Military HIV Research Program and the Thai Ministry of Health.
  • For HVTN 702, the vaccine regimen was adapted to the HIV subtype Clade C most common in southern Africa, where the pandemic is most pervasive.
  • David Dodd, GeoVax President & CEO, commented, The failure of the HVTN 702 vaccine regimen to prevent HIV infection is a disappointment to everyone in the field, especially to those most closely associated with the conduct of the trial.
  • GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel vaccine platform (GV-MVA-VLPTM).

AID FOR AIDS RAISES $1.3 MILLION DOLLARS AT ITS 2019 MY HERO GALA

Retrieved on: 
Tuesday, November 26, 2019
HIV/AIDS, Pandemics, Health, HIV/AIDS in South Africa

New York, NY, Nov. 26, 2019 (GLOBE NEWSWIRE) -- AID FOR AIDS International, Inc. raised over 1.3 million dollars at its signature My Hero Gala on Monday, November 25th.

Key Points: 
  • New York, NY, Nov. 26, 2019 (GLOBE NEWSWIRE) -- AID FOR AIDS International, Inc. raised over 1.3 million dollars at its signature My Hero Gala on Monday, November 25th.
  • Gatherings like AID FOR AIDS My Hero Gala serve as a reminder for people to unite and help transform the lives of those who are most at risk said Jesus Aguais, executive director and founder of AID FOR AIDS.
  • AID FOR AIDS and AID FOR LIFEs mission is to slow this tragic situation and focus on the most vulnerablenewborn babiesto ensure their survival.
  • AID FOR AIDS International is a non-for profit organization founded in 1996 with headquarters in New York City.

Bernie Sanders Becomes First Candidate to Support Curing AIDS During Q&A with Research Foundation to Cure AIDS

Retrieved on: 
Monday, October 21, 2019
Health, HIV/AIDS, Pandemics, Virology, HIV/AIDS activism, HIV/AIDS in South Africa, William A. Haseltine

Sanders' comprehensive position on curing AIDS was obtained by Research Foundation to Cure AIDS (RFTCA) .So far Sanders is the first and ONLY candidate to respond to all 10 questions posed by RFTCAPresident, Kambiz Shekdar, Ph.D. Sanders believes the U.S. can lead the development of a global cure for AIDS.

Key Points: 
  • Sanders' comprehensive position on curing AIDS was obtained by Research Foundation to Cure AIDS (RFTCA) .So far Sanders is the first and ONLY candidate to respond to all 10 questions posed by RFTCAPresident, Kambiz Shekdar, Ph.D. Sanders believes the U.S. can lead the development of a global cure for AIDS.
  • "We now have all of the tools we need to end AIDS deaths and HIV transmission and develop a cure for AIDS.
  • The author is a biologist, a biotech inventor, a gay man and the President of Research Foundation to Cure AIDS (RFTCA).
  • RFTCA paid $1.00for a perpetual worldwide license to cellular biotehnology to research, develop and commercialize a cure for AIDS.

Contagion® Launches HIV Screening, Prevention, and Treatment Advance Video Series

Retrieved on: 
Tuesday, April 9, 2019
Health, AIDS, Hospitals, Infectious diseases, Other Health, Research, Other Science, Science, Prevention of HIV/AIDS, HIV/AIDS in South Africa, HIV/AIDS, HIV/AIDS in China

The video series welcomes several experts in the treatment and management of HIV who provide peer-to-peer dialogue, insights, opinions, and perspectives on current trends and available treatments for patients with HIV.

Key Points: 
  • The video series welcomes several experts in the treatment and management of HIV who provide peer-to-peer dialogue, insights, opinions, and perspectives on current trends and available treatments for patients with HIV.
  • The first segment of this Peer Exchange series delves into a discussion on screening and prevention of HIV.
  • In the second segment, the experts provide a brief overview of the current HIV treatment landscape.
  • In the final segment, our experts discuss upcoming treatment options that are exciting for the HIV community.